High prevalence of type 2 diabetes and pre-diabetes in adult Zoroastrians in Yazd, Iran: a cross-sectional study

Saeedhossein Khalilzadeh, Mohammad Afkhami-Ardekani, Mohammadhosain Afrand

1Assistant Professor, Department of Endocrinology, Yazd Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
2Professor, Department of Endocrinology, Yazd Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3M.D, Medical Scientific Association, Ali-Ebne Abitaleb Faculty of Medicine, Islamic Azad University, Yazd Branch, Yazd, Iran

Type of article: Original

Abstract

Background: The prevalence of type 2 diabetes mellitus (T2DM) varies among ethnic groups. We aimed to estimate the prevalence of diagnosed and undiagnosed diabetes mellitus, impaired fasting glucose (IFG), and impaired glucose tolerance (IGT) for the first time in an ethnic population, specifically Zoroastrian citizens in Yazd, Iran whose ages were 30 or older.

Methods: In a cross-sectional study, participants aged ≥30 years were selected using systematic random sampling. An inventory, including socio-demographic data, was completed. Weight, height, body mass index (BMI), and blood pressure (BP) were measured using standard methods. Also, blood levels of glucose, triglycerides (TG), total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), urea, creatinine (Cr), and uric acid were measured. The latest criteria established by the American Diabetes Association (ADA) were used to diagnose DM.

Results: The mean age of the participants (n=403) was 56.9±12.8 years. The total prevalence of diabetes, including previously diagnosed and undiagnosed diabetes, IFG, and IGT was 26.1%, 18.6%, 7.5%, 34.7% and 25.8%, respectively. Participants with diabetes had higher fasting blood sugar (FBS) (P<0.001), oral glucose tolerance test (OGTT) (P<0.001), urea (P=0.019), BMI (P=0.001), systolic blood pressures (P<0.001), TG (P=0.007) and lower HDL (P=0.034) than patients with IFG, IGT, and normoglycemic subjects.

Conclusions: The current study showed a high prevalence of T2DM in the Zoroastrian population of Yazd, Iran. One-third of the total cases with diabetes were undiagnosed.

Keywords: type 2 diabetes, ethnic group, prevalence, pre-diabetes

1. Introduction

1.1. Background

The prevalence and incidence of type 2 diabetes mellitus (T2DM) are high in the Middle Eastern countries (1), and it has been estimated that these countries will have the largest increases in the prevalence of diabetes by 2030 (2). The prevalence of T2DM was determined to be 14.52% in Yazd, Iran (3). Environmental factors, including urbanization and a westernized lifestyle, as well as genetic susceptibility, can be considered as possible etiologies of the T2DM epidemic in Asia (4).

Corresponding author:
Dr. Mohammadhosain Afrand, Medical Scientific Association, Islamic Azad University, Safaiyeh Boulevard Daneshgah, Ali-Ebne Abitaleb Faculty of Medicine, Yazd, Iran. Postal code: 8917145438, Tel: +98.3517237280, Fax: +98.3515231421, Email: Afrand@iauyazd.ac.ir
Received: December 05, 2014, Accepted: January 20, 2015, Published: March 01, 2015
© 2015 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
1.2. Statement of the problem and objectives

The prevalence of T2DM exhibits variations among ethnic groups (5). Pima Indian adolescents (15 to 19 years of age) have the highest reported prevalence of T2DM among youth in the United States (6). A lot of people with T2DM remain unidentified (7). It has been reported that undiagnosed T2DM and impaired glucose regulation are very important clinically since they increase the risk of cardiovascular morbidity and mortality (8-11). In addition, due to the fact that the subjects remain untreated and at risk for complications, undiagnosed diabetes can have significant public health implications (7). Although it is feasible to screen for undiagnosed diabetes within a general practice by measuring fasting blood glucose, it would be better to target individuals with multiple risk factors for diabetes (12). Although Iranian people are mostly Muslims, there is an ethno-religious minority in Iran that practices Zoroastrianism, representing approximately 0.02-0.05% of the population. Zoroastrianism originated between the ninth and sixth centuries BC and was introduced by Sassanid as the official religion during the last pre-Islamic Persian Empire (13). In the last millennium, Zoroastrians have lived in a high level of isolation as well as endogamy, and this condition has been maintained vigorously to date. This enabled the survival of most of the mtDNA of their indigenous Iranian ancestors since there were no foreign contributions to their gene pool in the recent past (14). This provides an outstanding opportunity to study risk factors associated with T2DM in a setting in which genetic variability is limited. Most of this population is distributed throughout the Tehran, Kerman, and Yazd Provinces. We evaluated the prevalence of T2DM, impaired fasting glucose (IFG), and impaired glucose tolerance (IGT) for the first time in this ethnic population in Yazd, Iran, among people whose ages ranged from 30 to 88.

2. Materials and Methods

2.1. Study setting and selection criteria

In a community-based, cross-sectional study of inhabitant Zoroastrians of Yazd, Iran, a number of people aged between 30 and 88 years using systematic random sampling was selected from 14 locations representative of the distribution of the Zoroastrians population in Yazd. A letter was sent with all necessary information to those identified, requesting their collaboration and including eating requirements for the 3 days prior to the test and the need for fasting for at least 12-14 hours before the test. Of 410 letters sent, 408 were received, and 406 people took part in the study. Comparing sex and age distribution of those who did not respond and of those who took part in the study, we found there was no significant difference. The study was concluded in July 2013. Individuals were excluded from the analysis if they had a missing fasting (n=2) or 2-hours glucose value (n=1). Finally, 403 participants whose ages were ≥30 were included in the current data analysis.

2.2. Ethical consideration

The study’s protocol was approved by the Medical Ethics Committee of Yazd Islamic Azad University of Medical Sciences. The ethical committee of the research institute for endocrine sciences of Shahid Sadoughi University approved design of the study. Written informed consent forms were collected from all participants. The subjects were invited to the Yazd Diabetes Research Center.

2.3. Data Collection

An inventory was completed for all the subjects by a trained examiner. The inventory included age; gender; job; education; and history of hypertension, hyperlipidemia, alcohol consumption, and family history of diabetes mellitus (DM). The subjects’ weights were measured to the nearest 0.1 kg using a calibrated scale (Seca 220, Seca GmbH & Co. KG., Hamburg, Germany) with the subjects wearing light clothing and standing in an upright position. The subjects’ heights were measured to the nearest 0.5 cm using a standard stadiometer (Seca 220, Seca GmbH & Co. KG., Hamburg, Germany) while the subjects were not wearing shoes. Body mass index (BMI) was calculated by dividing weight (kg) by height squared (m²). After a 10-minute rest, the subjects’ blood pressure (BP) was measured twice (on a single occasion) by a standard mercury sphygmomanometer. The measurements were made to an accuracy of the nearest 2 mmHg while the subjects were in a seated position.

After 12-14 hours of overnight fasting, venous blood samples were taken from the subjects and analyzed in the laboratory of the Yazd Diabetes Research Center. An oral glucose tolerance test (OGTT) was conducted using 75-gm oral glucose powder. Blood levels of glucose, triglycerides (TG), total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), urea, creatinine (Cr), and uric acid were measured by an autoanalyzer (AMS Autolab, Italy) using pertinent Pars Azmun kits (Pars Azmun Co, Tehran, Iran), i.e., GOD-PAP for glucose, CHOD-PAP for TC, GPO-PAP for TG, ENZYMATIC for LDL, and PERCIPITANT for HDL. The latest criteria established by the American Diabetes Association (ADA) were used for the diagnosis of DM in the subjects (15).
2.4. Statistical Analysis
After entry, the data were analyzed using SPSS software, version 17 (SPSS Inc., Chicago, IL). Descriptive quantitative methods (measures of central tendency and dispersion) as well as ANOVA and chi-squared tests were used, where appropriate. Fisher's exact test was employed for measure relationship between age and prevalence of different glucose intolerance categories. P values ≤ 0.05 were considered to be statistically significant.

3. Results
3.1 Demographic findings
After applying the inclusion and exclusion criteria, 403 subjects were enrolled in the study. One hundred and fifty-three (38%) were male, and 250 (62%) were female. The mean age of the subjects was 56.9±12.8 years (range: 30-88 years). Abnormal glucose tolerance was more common in subject who married than in subjects who were single and widow, but there was no significant difference between marital status and abnormal glucose tolerance (P=0.062). There were significant difference between type of job, educational level and abnormal glucose tolerance, in while subject who were homemaker and have diploma, abnormal glucose tolerance was more common (P=0.022 and P<0.001, respectively). Subject who consume alcohol have less prevalent abnormal glucose tolerance than who do not (P=0.959) (Table 1). Among the married and widowed subjects, 152 (37.5%) were endogamous and 239 (59.3%) exogamous. Family histories of DM were found in 43.2% of the subjects. Histories of hypertension and/or taking anti-hypertensive drugs were found in 125 (31%) subjects. Histories of hyperlipidemia and/or taking anti-hyperlipidemic agents were found in 111 (27.5%) of the subjects.

Table 1. Association of demographic finding and abnormal glucose tolerance

| Demographic factors | Total | Abnormal glucose tolerance n (%) | P      |
|---------------------|-------|---------------------------------|--------|
| Marital status      |       |                                 |        |
| Single              | 14    | 5 (35.7)                        | 0.062  |
| Married             | 349   | 136 (39)                        |        |
| Widow               | 40    | 8 (20)                          |        |
| Job                 |       |                                 | 0.022  |
| Office worker       | 40    | 22 (55)                         |        |
| Worker              | 16    | 10 (62.5)                       |        |
| Homemaker           | 178   | 60 (33.7)                       |        |
| Farmer              | 10    | 3 (30)                          |        |
| Retired             | 113   | 35 (31)                         |        |
| Self-employed       | 46    | 19 (41.3)                       |        |
| Education           |       |                                 | <0.001 |
| Illiterate          | 22    | 5 (22.7)                        |        |
| Primary school      | 86    | 15 (17.4)                       |        |
| Guidance school and High school | 21 | 8 (38.1) |        |
| Diploma             | 207   | 78 (37.7)                       |        |
| Associates degree or higher | 67 | 43 (64.2) |        |
| Alcohol consumption |       |                                 | 0.959  |
| Yes                 | 144   | 53 (36.8)                       |        |
| No                  | 259   | 96 (37.1)                       |        |

Diabetes was found in 105 (26.1%) of the subjects. The prevalence of diabetes was higher in women (28%) than in men (22.9%), but the difference was not significant (P=0.255). The greatest total number of diabetic subjects was among those who were older than 50, and the peak prevalence was observed among individuals in the age range of 60-69 (37%). Also, it was found that 140 (34.7%) and 104 (25.8%) had IFG and IGT, respectively. Pearson’s correlation coefficient for test showed that the correlation between age and prevalence of previously diagnosed diabetes was 0.230 (P<0.001), between age and prevalence of undiagnosed diabetes was 0.174 (P<0.001), and between age and total prevalence of diabetes was 0.281 (P<0.001). There were no significant differences in the prevalence of diabetes (P=0.255), IFG (P=0.728), or IGT (P=0.296) by gender (Table 2).

3.2. Anthropometric and metabolic characteristics by glucose tolerance categories
We evaluated association of anthropometric and metabolic characteristics between subjects with NFG/NGT and subjects who had DM, IFG and IGT. In the subjects, all anthropometric and metabolic characteristics (except for TC, HDL-cholesterol, and LDL-cholesterol) were higher among those who had any glucose abnormality than among
those who had normal glucose tolerance (NGT) (Table 3). Overall, the subjects with diabetes had higher cardiovascular disease risk profiles than did the NGT subjects or the subjects with IFG and IGT.

**Table 2.** Age and gender prevalence of different glucose intolerance categories among Zoroastrian adults

| Gender | Previously diagnosed n (%) | Newly diagnosed (undiagnosed) n (%) | Total prevalence n (%) | IFG n (%) | IGT n (%) |
|--------|---------------------------|------------------------------------|------------------------|----------|----------|
| Male   | 23 (15)                   | 12 (7.9)                           | 35 (22.9)              | 58 (37.9) | 38 (24.8) |
| Female | 52 (20.8)                 | 18 (7.2)                           | 70 (28)                | 82 (32.8) | 66 (26.4) |
| Total  | 75 (18.6)                 | 30 (7.5)                           | 105 (26.1)             | 140 (34.7)| 104 (25.8)|

| Age (year) | Previously diagnosed n (%) | Newly diagnosed (undiagnosed) n (%) | Total prevalence n (%) | IFG n (%) | IGT n (%) |
|------------|---------------------------|------------------------------------|------------------------|----------|----------|
| 30-39      | 0 (0)                     | 1 (3.1)                            | 1 (3.1)                | 8 (25)   | 4 (12.5) |
| 40-49      | 7 (7.1)                   | 5 (5)                              | 12 (12.1)              | 28 (28.3)| 13 (3.1) |
| 50-59      | 19 (19.4)                 | 6 (6.1)                            | 25 (25.5)              | 36 (36.7)| 30 (30.6)|
| 60-69      | 29 (31.5)                 | 5 (5.5)                            | 34 (37)                | 41 (44.6)| 31 (33.7)|
| 70-89      | 20 (24.4)                 | 13 (15.8)                          | 33 (40.2)              | 27 (32.9)| 26 (31.7)|

n: number of sample, IFG: impaired fasting glucose, IGT: impaired glucose tolerance

**Table 3.** Anthropometric and metabolic characteristics of participants by glucose tolerance categories

| Variables | NGT/NFG | DM | IFG | IGT |
|-----------|---------|----|-----|-----|
| FBS (mg/dl) | 89.3±6.4 | 145.5±52.4 | 108.8±6.9 | 110.1±21.6 |
| OGGT (mg/dl) | 100.6±20.4 | 223.9±58.1 | 148.3±46.2 | 166.2±17.2 |
| TG (mg/dl) | 166.6±67.4 | 195.2±83.5 | 181±73.1 | 168.4±69.1 |
| TC (mg/dl) | 201.8±37.4 | 197.7±37.6 | 198.1±36.7 | 197.7±36.7 |
| LDL (mg/dl) | 126.7±24.9 | 119.1±23.1 | 121.8±25.2 | 121.6±25.6 |
| HDL (mg/dl) | 41.3±9.3 | 38.6±9 | 40.2±9 | 39.8±9 |
| Urea (mg/dl) | 32.9±9.9 | 36.4±12.2 | 35.4±9.5 | 34.4±8.7 |
| Cr (mg/dl) | 0.98±0.30 | 0.952 | 0.98±0.20 | 0.96±0.19 |
| UA (mg/dl) | 5.1±1.3 | 5.31±1.21 | 5.33±1.15 | 5.11±1.24 |
| BMI (kg/m²) | 25.5±3.6 | 27.2±3.9 | 26.4±3.5 | 26±3.5 |
| SBP (mmHg) | 122.06±16.3 | 134.4±18.2 | 129.6±15.2 | 129.6±14.9 |
| DBP (mmHg) | 78.09±11.09 | 80.9±10.3 | 82.6±10.5 | 81.1±9.8 |

* Compare variables mean between four glucose tolerance categories; † Compare variables mean between NGT and DM; ‡ Compare variables mean between NGT and IFG; § Compare variables mean between NGT and IGT

**4. Discussion**

In a population-based study of Zoroastrians living in Yazd, Iran, we reported the prevalence of previously diagnosed diabetes, undiagnosed (or newly diagnosed) diabetes, IFG, and IGT. We found that more than two-thirds of Zoroastrian adults whose ages were ≥30 were affected by some degree of hyperglycemia. Approximately 26.1% of all participants were known to have diabetes, of whom about one-third were undiagnosed (or newly diagnosed). The reported prevalence of diabetes in the current study was more than four times the rate predicted by King et al. for Iranians in 2000. The prevalence of diabetes was estimated to be 5.5 and 5.7% in 1995 and 2000, respectively, and it...
has been projected to be 9.8% in 2025. As acknowledged, such studies are flawed by old data, the scarcity of data, and the assumptions used to make estimates (16).

4.1 Association of demographic factors and abnormal glucose tolerance

In our study, although the prevalence of T2DM was higher in subjects aged 70 and above compared to 30-39 years old group, it was lower than subjects aged 60-69 years. This may be related to malnutrition, insufficient care, higher mortality rate, and socioeconomic status of these subjects. T2DM was lower in subjects who consume alcohol than those who do not, but this was not statistically significant. Some studies have shown different results (17) that may be associated with age, sex, and amount of alcohol intake. Wakabayashi et al. showed that light drinking is associated with a lower risk of DM in Japanese men and women, while very heavy drinking is thought to increase the risk of DM in Japanese men (18).

Recently, the national prevalence of T2DM among Iranian citizens, aged 25 to 64, was reported to be 7.7%; of this percentage, half had undiagnosed diabetes (19). It seems that the prevalence of diabetes and prediabetic states among Iranian adults is the same as those reported by neighboring countries (20, 21). In Iran, abnormalities in glucose tolerance might be increased by the high prevalence of obesity and metabolic syndrome (22-25). It has been reported that undiagnosed diabetes is as prevalent as, or even more prevalent than, diagnosed diabetes (26-27). The proportion of undiagnosed diabetics to the total number of diabetics has been estimated to be 70% in Denmark (28), 60.6% in India (29), and 47% in Australia (30). The proportion reported in this study is in agreement with the results of a study of the U.S. population (31). In spite of the fact that improvements have been made in education and access to medical care in Iran that have increased the population’s awareness of diabetes, the percentage of undiagnosed cases has not decreased. Several studies have focused on the association between diabetes and gender, but the results have not been consistent (32-35). In our study, it was found that the total prevalence of T2DM in women was higher than in men (28 vs. 22.9%). This finding was confirmed by a national survey of diabetes in Iran (8.3% in women vs. 7.1% in men) (19), but the data were different from the data of the U.S (36) and Australia (30). The underlying cause of this difference could be the high prevalence of metabolic syndrome in Iranian women (22-23).

4.2 Association of Anthropometric and metabolic characteristics of participants and glucose tolerance categories

In this study, participants with no glucose abnormality showed lower HDL than those with NGT. This may be attributed to low mean of HDL in Iranians (37), which might be, in turn, due to industrialization, unhealthy diets, lifestyle changes, obesity, and smoking (38). However, some studies have shown that the 40-60% variations in plasma levels of HDL in different individuals are related to gene polymorphism (39). In the current study, IGT was more prevalent among women, whereas IFG was more prevalent among men. Furthermore, the data from a national survey on diabetes in Iran (19) and in the U.S. (36) both represented the higher prevalence of IFG in the male population. It was previously shown that IGT was more prevalent in women whereas IFG was more prevalent in men (32). Several studies have reported that the prevalence of diabetes increases with age (32-34). The current study showed that the prevalence of diagnosed and undiagnosed diabetes, IGT, and IFG in both genders increased with age. It was found that the cardiovascular risk profile of subjects with diabetes was higher than that of NGT subjects, as well as subjects with IFG and IGT. In a review study, Harris et al. stated that patients with undiagnosed diabetes are not as hyperglycemic as those with diagnosed diabetes, but they have substantial rates of risk factors for complications (40). First, according to the increasing prevalence of obesity (25) and diabetes (41) in our population, the reported figures in this study seem to be underestimated. Second, it is impossible to make causal inferences about the relationship between risk factors and undiagnosed T2DM in a cross-sectional study. Strength of the study is that, to the best of our knowledge, this is the first population-based study in Zoroastrians who live in Yazd, Iran, in which the prevalence of T2DM was estimated using both fasting blood sugar (FBS) and OGTT for determining of undiagnosed diabetes.

5. Conclusions

This study found that there is a high prevalence of T2DM and pre-diabetes in the adult Zoroastrian population of Yazd, Iran. The most concerning finding to emerge from this study was that about one-third of patients with diabetes were newly diagnosed. We found that the cardiovascular risk profiles of the subjects with diabetes were higher than NGT subjects and subjects who had IFG and IGT. Further studies on different ethnic groups around the world using the cohort methodology could be a good direction for future research on this issue.
Acknowledgments

The authors are sincerely grateful for all participants in the study. Special thanks to Mohammad Hossein Ahmadieh of Department of Epidemiology of Shahid Sadoughi University of Medical Sciences for his perfect assistance in statistical analysis.

Conflict of Interest:
There is no conflict of interest to be declared.

Authors’ contribution:
All of authors read and approved the final manuscript, and contributed in the research and manuscript preparation. M.A. was the principal investigator, contributed to the study design and researched data. S.K., wrote the manuscript, gathered data, reviewed, and edited it. M.A-A is the guarantor of this works and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References
1) Harati H, Hadaegh F, Saadat N, Azizi F. Population-based incidence of Type 2 diabetes and its associated risk factors: results from a six-year cohort study in Iran. BMC public health. 2009; 9:186.
2) Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes care. 2004 May; 27(5):1047-53.
3) Afkhami-Ardekani M, Vahidi S, Vahidi A, Ahmadie MH. The prevalence of type 2 diabetes mellitus on age of 30 years and above in Yazd province (Iranian population). Journal of Shahid Sadoughi University of Medical Science and Health Services 2001; 9(1):22-27.
4) Ghassemi H, Harrison G, Mohammad K. An accelerated nutrition transition in Iran. Public Health Nutr 2002, 5:149-155.
5) Shai I, Jiang R, Manson JE, Stampfer MJ, Willett WC, Colditz GA, et al. Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study. Diabetes care. 2006 Jul; 29(7):1585-90.
6) Carter JS, Pugh JA, Monterrosa A. Non-insulin-dependent diabetes mellitus in minorities in the United States. Ann Intern Med 1996; 125:221.
7) Franse LV, Di Bari M, Shorr RI, Resnick HE, van Eijk JT, Bauer DC, Newman AB, Pahor M: Type 2 diabetes in older well-functioning people: who is undiagnosed? Data from the Health, Aging, and Body Composition study. Diabetes care 2001, 24(12):2065-2070.
8) Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey. 1988-1994. Diabetes care 1998, 21(4):518-524.
9) Wilson PW, Cupples LA, Kannel WB: Is hyperglycemia associated with cardiovascular disease? The Framingham Study. Am Heart J 1991, 121(2 Pt 1):586-590.
10) Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339(4):229-234.
11) Unwin N, Shaw J, Zimmet P, Alberti KG: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002, 19(9):708-723.
12) Lawrence JM, Bennett P, Young A, Robinson AM: Screening for diabetes in general practice: cross sectional population study. Bmj 2001, 323(7312):548-551.
13) Boyce M. A History of Zoroastrianism – The Early Period. London, Brill Academic Publications, 1996.
14) Farjadjan S, Sazzini M, Tofanelli S, Castri L, Taglioli L, Pettener D, Ghaderi A, et al. Discordant patterns of mtDNA and ethno-linguistic variation in 14 Iranian Ethnic groups. Human heredity 2011; 72:73-84
15) Diagnosis and classification of diabetes mellitus. Diabetes care 2013; 36 Suppl 1:S67-74.
16) King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes care 1998, 21(9):1414-1431.
17) Björntorp P. Neuroendocrine perturbations as a cause of insulin resistance. Diabetes/metabolism research and reviews 1999; 15:427-441.
18) Wakabayashi I. Cross-sectional relationship between alcohol consumption and prevalence of metabolic syndrome in Japanese men and women. Journal of atherosclerosis and thrombosis 2010; 17:695-704.
19) Esteghamati A, Gouya MM, Abbasi M, Delavari A, Alikhani S, Alaedini F, et al. Prevalence of diabetes and impaired fasting glucose in the adult population of Iran: National Survey of Risk Factors for Non-Communicable Diseases of Iran. Diabetes care 2008, 31(1):96-98.
20) Al-Lawati JA, Al Riyami AM, Mohammed AJ, Jousilahti P. Increasing prevalence of diabetes mellitus in Oman. Diabet Med 2002, 19 (11): 954-957.
21) Gokcel A, Ozsahin AK, Sezgin N, Karakose H, Ertorer ME, Akbaba M, et al. High prevalence of diabetes in Adana, a southern province of Turkey. Diabetes care 2003, 26(11): 3031-3034.
22) Azizi F, Salehi P, Etemadi A, Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res Clin Pract 2003, 61(1):29-37.
23) Zabetian A, Hadaegh F, Azizi F. Prevalence of metabolic syndrome in Iranian adult population, concordance between the IDF with the ATPIII and the WHO definitions. Diabetes Res Clin Pract 2007, 77(2):251-257.
24) Azadbakht L, Mirmiran P, Shiva N, Azizi F. General obesity and central adiposity in a representative sample of Tehranian adults: prevalence and determinants. Int J Vitam Nutr Res 2005, 75(4): 297-304.
25) Azizi F, Azadbakht L, Mirmiran P. Trends in overweight, obesity and central fat accumulation among Tehranian adults between 1998-1999 and 2001-2002: Tehran lipid and glucose study. Ann Nutr Metab 2005, 49(1):3-8.
26) Mooy JM, Grootenhuis PA, de Vries H, Valkenburg HA, Bouter LM, Kostense PJ, et al. Prevalence and determinants of glucose intolerance in a Dutch caucasian population. The Hoorn Study. Diabetes care 1995, 18(9): 1270-1273.
27) Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Bmj 1998, 317(7155): 371-375.
28) Glumer C, Jorgensen T, Borch-Johnsen K. Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study. Diabetes care 2003, 26(8):2335-2340.
29) Mohan V, Deepa M, Deepa R, Shanthirani CS, Farooq S, Ganesan A, et al. Secular trends in the prevalence of diabetes and impaired glucose tolerance in urban South India--the Chennai Urban Rural Epidemiology Study (CURES-17). Diabetologia 2006, 49(6):1175-1178.
30) Dunstan DW, Zimet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes care 2002, 25(5):829-834.
31) Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes care 2006, 29(6):1263-1268.
32) Ramachandran A, Snehalatha C, Satyavani K, Vijay V. Impaired fasting glucose and impaired glucose tolerance in urban population in India. Diabet Med 2003, 20(3):220-224.
33) Jaber LA, Brown MB, Hammed A, Nowak SN, Zhu Q, Ghafoor A, et al. Epidemiology of diabetes among Arab Americans. Diabetes care 2003, 26(2):308-313.
34) Ozdemir L, Topcu S, Nadir I, Nur N, Arslan S, Sumer H. The prevalence of diabetes and impaired glucose tolerance in Sivas, Central Anatolia, Turkey. Diabetes care 2005, 28(4):795-798.
35) Ramachandran A, Snehalatha C, Kapur A, Vijay V, Mohan V, Das AK, et al. High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. Diabetologia 2001, 44(9):1094-1101.
36) Geiss LS, Pan L, Cadwell B, Gregg EW, Benjamin SM, Engelgau MM. Changes in incidence of diabetes in U.S. adults, 1997-2003. Am J Prev Med 2006, 30(5):371-377.
37) Azizi F, Raiszadeh F, Salehi P, Rahmani M, Emami H, Ghanbarian A, et al. Determinants of serum HDL-C level in a Tehran urban population: the Tehran Lipid and Glucose Study. Nutrition, metabolism, and cardiovascular diseases: NMCID 2002; 12:80-89
38) Heller DA, de Faire U, Pedersen NL, Dahlen G, McClearn GE. Genetic and environmental influences on serum lipid levels in twins. New England Journal of Medicine 1993; 328:1150-1156
39) Peacock JM, Arnett DK, Atwood LD, Myers RH, Coon H, Rich SS, et al. Genome Scan for Quantitative Trait Loci Linked to High-Density Lipoprotein Cholesterol The NHLBI Family Heart Study. Arteriosclerosis, thrombosis, and vascular biology 2001; 21:1823-1828
40) Harris MI, Eastman RC. Early detection of undiagnosed diabetes mellitus: a US perspective. Diabetes Metab Res Rev 2000, 16(4):230-236.
41) Hadaegh F, Zabetian A, Harati H, Azizi F. Waist/height ratio as a better predictor of type 2 diabetes compared to body mass index in Iranian adult men-a 3.6-year prospective study. Exp Clin Endocrinol Diabetes 2006, 114(6):310-315.